Changeflow GovPing Pharma & Healthcare 0.01% and 0.025% Atropine Eye Drops Combined Wi...
Routine Notice Added Final

0.01% and 0.025% Atropine Eye Drops Combined With Auricular Acupoint Stimulation for Myopia Control in Children

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH has registered a randomized, double-blind, placebo-controlled pilot trial (NCT07537166) evaluating low-dose atropine (0.01%, 0.025%) combined with auricular acupoint stimulation for myopia control in 420 children aged 6-12. Participants will be divided into six groups receiving different treatments or placebo over a 12-week follow-up period. The study aims to determine synergistic effects of combined therapy and establish safer treatment options for myopia, addressing corneal toxicity concerns associated with higher 0.05% atropine concentrations.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a clinical trial (NCT07537166) on ClinicalTrials.gov involving low-dose atropine eye drops at two concentrations combined with auricular acupoint stimulation for myopia control in children aged 6-12. The pilot study will enroll 420 participants across six treatment arms and monitor corneal endothelial changes over 12 weeks.

For clinical investigators and trial sponsors, this registry entry indicates a planned study addressing safety concerns with higher-dose atropine (0.05%) by evaluating lower concentrations. The study may influence future pediatric ophthalmology research protocols and potential treatment guidelines for myopia management.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium Change

N/A NCT07537166 Kind: NA Apr 17, 2026

Abstract

This randomized, double-blind, placebo-controlled pilot trial evaluates the efficacy and safety of low-dose atropine (0.01%, 0.025%) combined with auricular acupoint stimulation for myopia control in children. While 0.05% atropine is effective, it may pose corneal toxicity risks, highlighting the need for safer alternatives. Auricular acupuncture has shown potential benefits in systematic reviews.

A total of 420 children aged 6-12 will be randomized into six groups receiving different treatments or placebo, with a 12-week follow-up. The auricular Eye Point will be stimulated, and comprehensive visual and ocular assessments will be conducted, including corneal endothelial monitoring.

This study aims to determine the synergistic effect of combined therapy and provide a safer treatment option, laying the foundation for future large-scale trials.

Conditions: Acupressure

Interventions: Auricular acupoint stimulation, 0.01% concentration atropine drops, 0.025% atropine eye drops, Artificial Tears (AT)

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07537166

Who this affects

Applies to
Clinical investigators Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial conduct Drug efficacy testing Medical device research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!